Outpatient Behavioral Health Clinic
Andrew Clark, MD
Chief of Outpatient Psychiatry
Shruti Shantharam, MPH
The Outpatient Behavioral Health Clinic serves approximately 60,000 patients annually for psychopharmacology and psychotherapy. Our providers see patients with complex behavioral health issues, including mood disorders, severe psychosis, and substance use. The leaders, managers, administrators, physicians and clinicians at the Outpatient Behavioral Health Clinic are committed to providing comprehensive, high quality, accessible and culturally appropriate care to their large and diverse patient population. This challenge requires ongoing research initiatives to understand, and subsequently improve aspects of care including logistical clinic flow, patient engagement, patient satisfaction, clinician burnout, relative volume and burden of psychiatric needs, and so on. Findings from various quality improvement (QI) initiatives are critical to informing the ongoing improvement of outpatient services. The Outpatient Behavioral Health Clinic supports and encourages its staff to pursue research opportunities both within outpatient services and beyond.
Within the Outpatient Behavioral Health Clinic, there are various disorder-specific programs, each of which contain research components. These include the Psychotic Disorders Program and the First Episode Psychosis Program, with planned future expansions into other disorder-specific programs.
Psychotic Disorders Program
The Department of Psychiatry is engaged in a range of clinical trials with individuals with psychotic disorders, with an emphasis on schizophrenia research. For more information about the research conducted in the psychotic disorders program, please see the schizophrenia clinical trials listed on the Clinical Studies Unit webpage.
For more information about the clinical services available for individuals with psychotic disorders, please visit the Psychotic Disorders Program webpage.
First Episode Psychosis Program
The Outpatient Behavioral Health Clinic places specific emphasis on the needs of individuals who are experiencing a first episode of psychosis in order to facilitate earlier intervention and connection to treatment. We are initiating a longitudinal, observational, natural prospective study to better understand and care for this unique population. We are also currently engaged in a clinical trial of a new medication for the prevention of first episode psychosis in individuals with attenuated psychosis syndrome (APS). For more information about this study, please see the study listing on the Clinical Studies Unit webpage.
For more information about the clinical services available for individuals with first episode psychosis, please visit the Psychotic Disorders Program webpage.